Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
50.5 EUR | -0.20% | -0.39% | -2.32% |
04-29 | DRAEGERWERK : Hauck & Aufhauser reiterates its Buy rating | ZD |
04-25 | Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15 | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.31 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.32% | 934M | B+ | ||
+8.69% | 220B | B | ||
+6.69% | 183B | B- | ||
+10.90% | 133B | B- | ||
+25.41% | 107B | A- | ||
+0.15% | 63.05B | A- | ||
+12.72% | 51.74B | B+ | ||
+3.96% | 50.47B | B+ | ||
+0.40% | 40.91B | A | ||
+15.03% | 40.59B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DRW3 Stock
- Ratings Drägerwerk AG & Co. KGaA